U.S. Formulation Development Outsourcing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The u.S. formulation development outsourcing market size is expected to increase from USD 9.80 billion in 2025 to USD 10.66 billion in 2026 and reach USD 16.03 billion by 2031, growing at a CAGR of 8.5% over 2026-2031. This report is Segmented by Service Type (Preformulation, Formulation Development), Dosage Form (Oral, Injectable, Topical, Inhalation, Ophthalmic, Others), Therapeutic Area (Oncology, Infectious Disease, Neurology, Cardiovascular, Respiratory, Hematology, Dermatology, Rare Disease, Autoimmune, Others), End User (Pharma/Biopharma, Govt/Academic, Others). Forecasts in Value (USD).

U.S. Formulation Development Outsourcing Market Trends and Insights

Outsourcing To Control Cost And Access Formulation Expertise

The United States pharmaceutical formulation development services market is evolving with an asset-light R&D model, concentrating on outsourcing with a few full-service CDMOs. In 2025, 73% of FDA approvals used outsourced API manufacturing, consistent with 74% in 2024, while 65% relied on outsourced finished-dose manufacturing. Large pharmaceutical companies are adopting risk-sharing contracts with milestone and royalty components, favoring providers with strong regulatory performance. This trend is sidelining smaller CDMOs and increasing switching barriers, granting established providers greater pricing power as demand grows across clinical and commercial programs.

Rising Biologics And Injectable Complexity

The United States pharmaceutical formulation development services market is expanding due to the technical demands of biologics and sterile injectables. Biologics accounted for 45% of FDA approvals in 2025, with a focus on advanced therapies like antibody-drug conjugates and lipid nanoparticle RNA therapies. Platforms like WuXi Biologics’ WuXiHigh 2.0 highlight the importance of technical differentiation. Over 20% of monoclonal antibody products now use high-concentration formulations, with self-administered subcutaneous delivery gaining traction. Persistent fill-finish constraints have increased the value of domestic sterile capacity, benefiting CDMOs with advanced aseptic filling capabilities.

Stringent FDA CMC And Clinical Trial Compliance

Stringent FDA compliance continues to challenge the United States pharmaceutical formulation development services market by increasing costs and extending development timelines. From 2020 to 2024, 74% of complete response letters were linked to CMC and analytical gaps, often identified late in the review process after significant investments. For novel biologics, early focus on comparability planning, secondary supplier coverage, and validated cold-chain logistics adds pressure on smaller teams. CDMOs offering bundled regulatory advisory services gain an edge over those providing only laboratory execution. While the FDA's CDRP program accelerates breakthrough-designated programs, its impact remains limited to eligible cases.

Other drivers and restraints analyzed in the detailed report include:

• Oncology And Specialty Pipeline Expansion
• Dense US Clinical Trial Activity And Faster Development Timelines
• Early-Stage Biotech Funding Volatility

Segment Analysis

In 2025, Formulation Development Services accounted for 75.69% of the United States pharmaceutical formulation development services market, reflecting sponsors' preference for integrated partnerships that consolidate analytical, process, and scale-up tasks within a single quality system. Preformulation Services, growing at a 16.20% CAGR through 2031, highlights a shift toward early risk identification, with sponsors focusing on viscosity, aggregation tendencies, and excipient compatibility in biologics, ADCs, and lipid nanoparticle therapies. This approach minimizes late-stage reformulation and regulatory disruptions.

Injectable and Parenteral forms are the fastest-growing segment in the United States pharmaceutical formulation development services market, with a projected 16.99% CAGR through 2031. This growth is driven by the biologics-heavy approval landscape and the lack of sterile infrastructure among sponsors for complex development tasks. High-concentration subcutaneous products and proprietary excipient systems are increasingly in demand, rewarding specialized sterile formulation expertise.

Complete Report Scope:

• By Service Type
  • Preformulation Services
  • Formulation Development Services
• By Dosage Form
  • Oral
  • Injectable and Parenteral
  • Topical and Transdermal
  • Inhalation and Nasal
  • Ophthalmic
  • Buccal, Sublingual, Rectal, and Vaginal
• By Therapeutic Area
  • Oncology
  • Infectious Disease
  • Neurology
  • Cardiovascular
  • Respiratory
  • Hematology
  • Dermatology
  • Rare Disease and Genetic Disorders
  • Autoimmune and Inflammatory Disorders
  • Others
• By End User
  • Pharmaceutical and Biopharmaceutical Companies
  • Government and Academic Institutes
  • Others

List of Companies Covered in this Report:

• Adare Pharma Solutions
• Alcami
• Bend Bioscience
• Cambrex
• Catalent
• Charles River
• Curia Global, Inc.
• Evonik Health Care
• Intertek Group
• Jubilant HollisterStier LLC
• Lonza Group
• National Resilience
• PCI Pharma Services
• Piramal Group
• Quotient Sciences
• Recipharm
• Seran Bioscience
• SGS
• Simtra BioPharma Solutions
• Thermo Fisher Scientific Inc. (Patheon)

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support